Every material Form 8-K SS Innovations International, Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SS Innovations said its SSi Mantra robotic system and SSi MantrAsana tele-surgeon console were used in telesurgeries at two October 2026 medical conferences, in Barcelona and New Delhi. The filing is a promotional update and contains no financial results, guidance or financial statements, so it gives shareholders no new financial measures to assess.
Dr. Sudhir Srivastava performed a robotic cardiac telesurgery at the EACTS Annual Meeting in Barcelona, with the patient about 7,500 miles away in Bengaluru, India.
Four surgeons completed four robotic-assisted telesurgeries at the inaugural SRS India Conference in New Delhi.
As of October 23, 2026, a total of 205 telesurgeries had been performed with the SSi Mantra surgical robotic system.
SS Innovations said it submitted its response to an FDA request for additional information on its 510(k) application for the SSi Mantra surgical robotic system on October 5, 2026. The response includes final data from an expanded human clinical and human factors validation study and a bridging study, and the company expects the FDA to complete its review in the first quarter of 2027. The filing describes a regulatory milestone toward U.S. market entry but gives no financial results or timing guarantees.
Response to the FDA's request for additional information was submitted on October 5, 2026.
The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia in Bucaramanga.
The company expects the FDA to complete its review of the response and the 510(k) submission in the first quarter of 2027.
The 510(k) submission covers the initial indication of cholecystectomy (gallbladder removal).
SS Innovations International entered a Securities Purchase Agreement on October 9, 2026, issuing a secured convertible promissory note with a $21,025,000 principal amount for a $20,000,000 purchase price. The note bears 8.75% interest, matures 36 months after closing, and is secured by the company's intellectual property and most subsidiary assets, which could dilute existing shareholders through conversions.
Note issued October 9, 2026 with $21,025,000 principal for a $20,000,000 purchase price, including $1,000,000 original issue discount and $25,000 investor expenses
Interest at 8.75% per annum compounded daily; matures 36 months after the Closing Date
Investor may convert at 95% of Market Price beginning on the Effective Date; company reserved an initial 8,000,000 common shares for conversions
Note secured by company IP held by SSI IP Holdings and assets of the company and SS IP; Indian subsidiary SSI-India excluded from collateral
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SS Innovations International, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →